Author

Joseph P. Bluck

Bayer (Germany)ORCID 0000-0001-9170-5919Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:deep learning· 1 Approach:experimental assay· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Adam P. SkepneriD· 1 shared Alison LeediD· 1 shared Andrea VolkameriD· 1 shared Aziz M. RangwalaiD· 1 shared Bert L. de GrootiD· 1 shared C. PichloiD· 1 shared Clara D. ChristiD· 1 shared David SchalleriD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam P. SkepnerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 25, 2025

Phenotypic screening converges on CDK9 inhibition as a therapeutic strategy in translocation renal cell carcinoma

Dharma R. Thapa, Riva Deodhar, Adam P. Skepner…·Srinivas Raghavan Viswanathan

The paper identifies CDK9 inhibition as a therapeutic strategy for translocation renal cell carcinoma through phenotypic screening and mechanistic analysis.

1 citation

humanexperimental assay

𝕏 PostBluesky

BiophysicsThe Journal of Physical Chemistry BPeer-reviewedMar 7, 2025

Prospective evaluation of structure-based simulations reveal their ability to predict the impact of kinase mutations on inhibitor binding

Sukrit Singh, Vytautas Gapsys, Matteo Aldeghi…·John D. Chodera

The paper evaluates structure-based methods to predict how kinase mutations affect inhibitor binding, finding they accurately classify mutations as resistant or sensitizing.

16 citationstop 2%

humanproteomics

𝕏 PostBluesky